- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03861468
Medico-economics and QoL of Obese Patients Followed by Medical Analysis Laboratories (BIOSAOS ) (BIOSAOS)
January 3, 2023 updated by: University Hospital, Grenoble
Medico-economic and Quality of Life Evaluations in Obese Patients Followed by Medical Analysis Laboratories
Obesity is a major risk factor for obstructive sleep apnea (OSA).
However, OSA is still largely under diagnosed in patients with a high cardiovascular risk.
In this population the STOP-BANG questionnaire facilitates OSA screening.
Moreover, blood bicarbonate concentration is a simple tool to screen for chronic respiratory disease and if elevated, is a marker of cardiometabolic comorbidities in obese patients.
A combination of blood bicarbonate concentration and STOP BANG score could provide a cost-effective method of screening for OSA in obese patients.
Such screening could enable earlier management and might significantly reduce the costs of treatment and improve the quality of life of patients at 2 years.
Study Overview
Status
Withdrawn
Intervention / Treatment
Detailed Description
OSA is a frequent condition in the general population (3% of women and 10% of men), but remains largely undiagnosed.
Obesity is a risk factor for OSA.
Sleep apnea is associated with diurnal and nocturnal symptoms (snoring, somnolence, fatigue), and with increased cardiometabolic morbidity and mortality.
Currently, continuous positive airway pressure (CPAP) is the gold-standard treatment for OSA and the cost-effectiveness of this treatment has already been demonstrated.
Easy-to-use procedures to identify OSA patients earlier and thus to initiate treatment earlier, need to be developed and validated.
The STOP-BANG questionnaire has been designed to facilitate the screening of OSA patients.
Moreover, a measure of blood bicarbonate concentration is a simple method for screening for chronic respiratory diseases and a marker of cardiometabolic comorbidities.
A combination of blood bicarbonate measurement and STOP-BANG score could permit earlier screening and less expensive care of obese patients.
The hypothesize is that such OSA screening in the obese population (bicarbonates + STOPBANG) associated with earlier care (with treatment if necessary) could lead to improvement in quality of life of obese patients at 2 years.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Vizille, France
- ORIADE
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients aged from 18 to 80 years
- Obese (BMI ≥ 30kg/m²)
- Referred by GPs to the medical analysis laboratory for usual biological assessment
- Patients with no respiratory follow-up already in place
- Patient affiliated with a social protection plan
- Bicarbonate - Concentration ≥ 27 mmol/L
- STOP-BANG score ≥ 3
- Informed written consent signed by the patient
Exclusion Criteria:
- Acute disease or recently diagnosed chronic disease (< 2 months)
- Hospitalization for respiratory, metabolic or cardiovascular event (< 2 months)
- Renal insufficiency stage 4 or 5, or autoimmune disease, or viral hepatitis, or cirrhosis
- Cited persons in Sections L1121-5 to L1121-8 of the CSP (pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, a person who is the subject of a judicial or administrative legal protection)
- Patients already included in an interventional study (end of the study < 1 month)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Usual care
Patients in the usual care group will be referred to their general practitioner (GP) / primary care practitioner as usual.
|
|
Active Comparator: Early care
A different care pathway will be followed by the patients randomized to this group.
They will be referred to a specialist (pneumologist) for OSA diagnosis and treatment if necessary
|
Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-year medico-economic impact of the implementation of early care in obese patients with OSA
Time Frame: 24 months
|
incremental cost-effectiveness ratio at 24 months calculated from the difference in healthcare costs between the 2 groups (early care vs usual care) adjusted to the difference in the number of quality adjusted life years
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Economic impact of the implementation of early care in obese patients with OSA over 3 years on the healthcare costs
Time Frame: 3 years
|
The economic impact on healthcare costs from the Health Insurer's perspective will be calculated from the difference in healthcare costs between the two groups (early care vs usual care)
|
3 years
|
To evaluate the sensitivity of the screening tool
Time Frame: 24 months
|
The sensitivity will be evaluated by comparison with polysomnography
|
24 months
|
To evaluate the specificity of the screening tool
Time Frame: 24 months
|
The specificity will be evaluated by comparison with polysomnography
|
24 months
|
To evaluate the negative Predictive Value
Time Frame: 24 months
|
The negative predictive value will be evaluated by comparison with polysomnography
|
24 months
|
To evaluate the positive predictive value of the screening tool
Time Frame: 24 months
|
The positive predictive value will be evaluated by comparison with polysomnography
|
24 months
|
Clinical impact of the early care pathway on blood pressure at 12 months
Time Frame: 12 months
|
Blood pressure at home
|
12 months
|
Clinical impact of the early care pathway on blood pressure at 24 months
Time Frame: 24 months
|
Blood pressure at home
|
24 months
|
Clinical impact of the early care pathway on quality of life at 12 months
Time Frame: 12 months
|
The EQ-5D-5L health status questionnaire, This scale is numbered from 0 to 100. 100 means the best health status.
0 means the worst health status.
|
12 months
|
Clinical impact of the early care pathway on quality of life at 24 months
Time Frame: 24 months
|
The EQ-5D-5L health status questionnaire, This scale is numbered from 0 to 100. 100 means the best health status.
0 means the worst health status.
|
24 months
|
Clinical impact of the early care pathway (early care) on quality of life at 12 months
Time Frame: 12 months
|
Stroke and Aphasia Quality of Life Scale (SAQOL), This questionnaire is intended to study the relationship between sleep and the quality of life.
This scale is numbered from 0 to 4. higher values represent a worse outcome
|
12 months
|
Clinical impact of the early care pathway (early care) on quality of life at 24 months
Time Frame: 24 months
|
Stroke and Aphasia Quality of Life Scale (SAQOL), This questionnaire is intended to study the relationship between sleep and the quality of life.
This scale is numbered from 0 to 4. higher values represent a worse outcome
|
24 months
|
Clinical impact of the early care pathway on pharmacological treatments at 12 months
Time Frame: 12 months
|
number of pharmacological treatments
|
12 months
|
Clinical impact of the early care pathway on pharmacological treatments at 24 months
Time Frame: 24 months
|
number of pharmacological treatments
|
24 months
|
Impact on laboratory test results (troponin) at 12 months
Time Frame: 12 months
|
troponin
|
12 months
|
Impact on laboratory test results (troponin) at 24 months
Time Frame: 24 months
|
troponin
|
24 months
|
Impact on laboratory test results (NT-proBNP) at 12 months
Time Frame: 12 months
|
NT-proBNP
|
12 months
|
Impact on laboratory test results (NT-proBNP) at 24 months
Time Frame: 24 months
|
NT-proBNP
|
24 months
|
Impact on laboratory test results on cholesterol at 12 months
Time Frame: 12 months
|
cholesterol
|
12 months
|
Impact on laboratory test results on cholesterol at 24 months
Time Frame: 24 months
|
cholesterol
|
24 months
|
Impact on laboratory test results on triglycerides at 12 months
Time Frame: 12 months
|
triglycerides
|
12 months
|
Impact on laboratory test results on triglycerides at 24 months
Time Frame: 24 months
|
triglycerides
|
24 months
|
Impact on laboratory test results on glycaemia at 12 months
Time Frame: 12 months
|
glycaemia
|
12 months
|
Impact on laboratory test results on glycaemia at 24 months
Time Frame: 24 months
|
glycaemia
|
24 months
|
Impact on laboratory test results on Homeostasis model assessment (HOMA)-index at 12 months
Time Frame: 12 months
|
Homeostasis model assessment (HOMA)-index
|
12 months
|
Impact on laboratory test results on Homeostasis model assessment (HOMA)-index at 24 months
Time Frame: 24 months
|
Homeostasis model assessment (HOMA)-index
|
24 months
|
Impact on laboratory test results on hepatic transaminases at 12 months
Time Frame: 12 months
|
transaminases (ASAT, ALAT)
|
12 months
|
Impact on laboratory test results on hepatic transaminases at 24 months
Time Frame: 24 months
|
transaminases (ASAT, ALAT)
|
24 months
|
Impact on laboratory test results on creatinine at 12 months
Time Frame: 12 months
|
creatinine
|
12 months
|
Impact on laboratory test results on creatinine at 24 months
Time Frame: 24 months
|
creatinine
|
24 months
|
Impact on laboratory test results on C-Reactive Protein (CRP) at 12 months
Time Frame: 12 months
|
C-Reactive Protein (CRP)
|
12 months
|
Impact on laboratory test results on C-Reactive Protein (CRP) at 24 months
Time Frame: 24 months
|
C-Reactive Protein (CRP)
|
24 months
|
Impact on laboratory test results on alpha2-macroglobulin at 12 months
Time Frame: 12 months
|
alpha2-macroglobulin
|
12 months
|
Impact on laboratory test results on alpha2-macroglobulin at 24 months
Time Frame: 24 months
|
alpha2-macroglobulin
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jean-Louis PEPIN, MD, PhD, Grenoble Alpes University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 14, 2019
Primary Completion (Actual)
December 6, 2022
Study Completion (Actual)
December 6, 2022
Study Registration Dates
First Submitted
February 22, 2019
First Submitted That Met QC Criteria
March 1, 2019
First Posted (Actual)
March 4, 2019
Study Record Updates
Last Update Posted (Actual)
January 5, 2023
Last Update Submitted That Met QC Criteria
January 3, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Apnea
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Overnutrition
- Nutrition Disorders
- Signs and Symptoms, Respiratory
- Respiratory Insufficiency
- Obesity
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Hypoventilation
- Obesity Hypoventilation Syndrome
Other Study ID Numbers
- 38RC17.360
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
LivaNovaRecruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
State Budgetary Healthcare Institution, National...RecruitingObstructive Sleep Apnea | Obstructive Sleep Apnea-hypopnea | Obstructive Sleep Apnea-hypopnea SyndromeRussian Federation
-
The Hospital for Sick ChildrenCompleted
-
Cryosa, Inc.Active, not recruitingObstructive Sleep Apnea of AdultPanama, Paraguay
-
State Key Laboratory of Respiratory DiseaseCompletedObstructive Sleep Apnea of AdultChina
-
Somnics, Inc.UnknownObstructive Sleep Apnea of AdultTaiwan
-
ResMedCompletedObstructive Sleep Apnea (OSA)United States, Australia
Clinical Trials on Care pathway
-
European Pathway AssociationKU Leuven; University of Eastern PiedmontCompletedPulmonary Disease, Chronic Obstructive
-
European Pathway AssociationKU Leuven; University of Eastern PiedmontCompleted
-
European Pathway AssociationKU LeuvenCompleted
-
Helsinki University Central HospitalRecruitingEncephalitis | Traumatic Brain Injury | Hypoxia-Ischemia, Brain | Brain Hemorrhage | Stroke, Acute IschemicFinland
-
Medical College of WisconsinPediatric Emergency Care Applied Research Network; Nemours Children's Health...RecruitingSickle Cell CrisisUnited States
-
Dr. Kris VanhaechtKU Leuven; University of Eastern PiedmontCompletedChronic Obstructive Pulmonary Disease | Proximal Femur FractureBelgium
-
St Luke's Hospital, SingaporeNational University, SingaporeCompleted
-
Ilyse KenisKU Leuven; University Ghent; Kom Op Tegen KankerUnknownOncologic DisordersBelgium
-
Norwegian University of Science and TechnologyThe Research Council of Norway; St. Olavs Hospital; Nordmøre and Romsdal Hospital... and other collaboratorsCompleted
-
Majed AljeraisyCompletedHeart Failure | Asthma | Acute Kidney Injury | Venous Thromboembolism | Community Acquired PneumoniaSaudi Arabia